Zoledronic AcidA Review of its Use in the Management of Bone Metastases and Hypercalcaemia of Malignancy

[1] Pelger RCM(2001)Strategies for management of prostate cancer-related bone pain Drugs Aging 18 899-911

[2] Soerdjbalie-Maikoe V(1998)Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review J Clin Oncol 16 1218-25

[3] Hamdy NAT(2000)American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18 1378-91

[4] Bloomfield DJ(1997)Malignant bone pain: pathophysiology and treatment Pain 69 1-18

[5] Hillner BE(2002)Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10 399-407

[6] Ingle JN(2002)American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma J Clin Oncol 20 3719-36

[7] Berenson JR(2002)Hypercalcemia of malignancy: diagnosis and treatment options Am J Cancer 1 277-92

[8] Mercadante S(1998)The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials Pain 78 157-69

[9] Body JJ(1998)Pamidronate: a review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget’s disease of bone Drugs Aging 12 149-68

[10] Mancini I(2001)Zoledronic acid Drugs 61 799-805

[1] Pelger RCM(2001)Strategies for management of prostate cancer-related bone pain Drugs Aging 18 899-911

[2] Soerdjbalie-Maikoe V(1998)Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review J Clin Oncol 16 1218-25

[3] Hamdy NAT(2000)American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18 1378-91

[4] Bloomfield DJ(1997)Malignant bone pain: pathophysiology and treatment Pain 69 1-18

[5] Hillner BE(2002)Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10 399-407

[6] Ingle JN(2002)American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma J Clin Oncol 20 3719-36

[7] Berenson JR(2002)Hypercalcemia of malignancy: diagnosis and treatment options Am J Cancer 1 277-92

[8] Mercadante S(1998)The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials Pain 78 157-69

[9] Body JJ(1998)Pamidronate: a review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget’s disease of bone Drugs Aging 12 149-68

[10] Mancini I(2001)Zoledronic acid Drugs 61 799-805